Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

After Imbruvica Passes Chemo-Free Tests, Shorter Duration Regimens Could Be Next Value-Adds

Dec 13 2018

• By Mandy Jackson

Ladder made of coins with colorful pills on top suggesting the growing prices of medicine or drugs

Related Content

Imbruvica Replaces Chemo, Darzalex Boosts Standard Of Care In Front-Line CLL, Myeloma

Dec 05 2018

Pharmacyclics clinches $150 million up front from Janssen in blood cancer deal

Dec 09 2011

AbbVie outdoes rumored J&J bid with $21bn Pharmacyclics buy

Mar 05 2015

ASH Preview: Practice-Changing Darzalex And Imbruvica, Advances In Beta-Thalassemia And More

Nov 29 2018

Related Companies

AbbVie Inc.

Johnson & Johnson

Johnson & Johnson

Pharmacyclics, Inc.

Roche Holding AG

Genentech, Inc.

Biogen, Inc.

Additional Topics

Reimbursement Business Strategies Companies Commercial Cancer BioPharmaceutical

More from Anticancer

More from Therapy Areas

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window